bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Should You Sell?

bioMerieux (OTCMKTS:BMXMF)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $84.0750, but opened at $78.16. bioMerieux shares last traded at $78.16, with a volume of 65 shares traded.

Analyst Ratings Changes

A number of brokerages recently issued reports on BMXMF. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of bioMerieux in a report on Wednesday. Zacks Research upgraded shares of bioMerieux to a “hold” rating in a report on Tuesday, April 28th. Piper Sandler began coverage on shares of bioMerieux in a report on Thursday, June 11th. They issued a “neutral” rating for the company. Finally, UBS Group cut shares of bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Five equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, bioMerieux presently has an average rating of “Hold”.

bioMerieux Price Performance

The stock’s 50-day simple moving average is $89.90 and its two-hundred day simple moving average is $108.75. The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.